MBD4

methyl-CpG binding domain 4, DNA glycosylase, the group of DNA glycosylases|Methyl-CpG binding domain containing

Basic information

Region (hg38): 3:129430947-129440179

Links

ENSG00000129071NCBI:8930OMIM:603574HGNC:6919Uniprot:O95243AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • tumor predisposition syndrome 2 (Moderate), mode of inheritance: AR
  • tumor predisposition syndrome 2 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Uveal melanoma, susceptibility to, 1; Tumor predisposition syndrome 2AD/AROncologicUveal melanoma, susceptibility to involves increased risk of uveal melanoma, and awareness may enable early identification and management (positive response to pembrolizumab has been described); Tumor predisposition syndrome 2 can involve increased risk of a number of different types of cancer, including hematologic malignancy as well as solid tumors, and awareness may enable early identification and management of cancer-related manifestationsOncologic29760383; 30049810; 30714079; 31322271; 32239153; 35460607
Heterozygous variants can also be involved in predisposition to uveal melanoma

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MBD4 gene.

  • not provided (26 variants)
  • Tumor predisposition syndrome 2 (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MBD4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
63
clinvar
2
clinvar
67
missense
191
clinvar
2
clinvar
4
clinvar
197
nonsense
6
clinvar
4
clinvar
10
start loss
0
frameshift
20
clinvar
20
inframe indel
7
clinvar
7
splice donor/acceptor (+/-2bp)
4
clinvar
1
clinvar
5
splice region
6
4
1
11
non coding
5
clinvar
32
clinvar
10
clinvar
47
Total 26 4 210 97 16

Highest pathogenic variant AF is 0.000197

Variants in MBD4

This is a list of pathogenic ClinVar variants found in the MBD4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
3-129431510-A-C Uncertain significance (Dec 17, 2023)2878139
3-129431522-A-G Likely benign (Dec 05, 2023)2700985
3-129431523-T-C Uncertain significance (Nov 03, 2023)2901762
3-129431538-C-T Melanoma, uveal, susceptibility to, 1 Uncertain significance (Oct 29, 2023)1700256
3-129431540-G-A Likely benign (Jan 24, 2024)2868672
3-129431542-C-G not specified Conflicting classifications of pathogenicity (Aug 01, 2024)218624
3-129431544-T-C Uncertain significance (Mar 19, 2023)2778045
3-129431545-G-A Uncertain significance (Jan 20, 2023)2830574
3-129431547-T-C Uncertain significance (Jan 28, 2024)2713871
3-129431549-T-C Likely benign (Dec 27, 2023)2870365
3-129431556-A-T Melanoma, uveal, susceptibility to, 1 • Tumor predisposition syndrome 2 Conflicting classifications of pathogenicity (Jan 29, 2024)1700254
3-129431559-T-C Uncertain significance (Dec 27, 2023)2871151
3-129431588-A-G Uncertain significance (Dec 12, 2023)2702360
3-129431590-A-G Uncertain significance (Jan 24, 2024)2867570
3-129431595-A-C Uncertain significance (Jan 17, 2024)2872041
3-129431596-T-C Likely benign (Dec 10, 2023)2702000
3-129431598-C-G Likely benign (Dec 18, 2023)2703857
3-129431751-A-C Benign (May 13, 2021)1277442
3-129432443-G-A MBD4-related disorder Likely benign (Dec 30, 2022)3053265
3-129432483-T-C Likely benign (Jan 04, 2024)2776969
3-129432487-T-C Likely benign (Jun 09, 2022)2003981
3-129432490-G-C Likely benign (Jan 18, 2024)1976601
3-129432492-G-A Likely benign (Nov 25, 2023)2795603
3-129432500-C-T Uncertain significance (Jan 02, 2024)3017227
3-129432513-T-A Uncertain significance (Dec 06, 2023)2782900

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MBD4protein_codingprotein_codingENST00000249910 89092
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.97e-140.05731256700781257480.000310
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.4602702920.9240.00001503817
Missense in Polyphen7087.4590.800371197
Synonymous-1.171181031.150.000005341064
Loss of Function0.5852326.20.8770.00000151342

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0005350.000535
Ashkenazi Jewish0.0001980.000198
East Asian0.0007610.000761
Finnish0.0001850.000185
European (Non-Finnish)0.0003600.000360
Middle Eastern0.0007610.000761
South Asian0.00009800.0000980
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Mismatch-specific DNA N-glycosylase involved in DNA repair. Has thymine glycosylase activity and is specific for G:T mismatches within methylated and unmethylated CpG sites. Can also remove uracil or 5-fluorouracil in G:U mismatches. Has no lyase activity. Was first identified as methyl-CpG-binding protein. {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10930409}.;
Pathway
Base excision repair - Homo sapiens (human);DNA Repair;Recognition and association of DNA glycosylase with site containing an affected pyrimidine;Cleavage of the damaged pyrimidine ;Depyrimidination;Base-Excision Repair, AP Site Formation;Resolution of Abasic Sites (AP sites);Base Excision Repair;Displacement of DNA glycosylase by APEX1 (Consensus)

Recessive Scores

pRec
0.177

Intolerance Scores

loftool
0.304
rvis_EVS
0.62
rvis_percentile_EVS
83.42

Haploinsufficiency Scores

pHI
0.425
hipred
N
hipred_score
0.341
ghis
0.499

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.986

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mbd4
Phenotype
embryo phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; digestive/alimentary phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; craniofacial phenotype;

Gene ontology

Biological process
DNA repair;response to radiation;response to estradiol;depyrimidination
Cellular component
chromatin;nucleus;nucleoplasm;nuclear speck
Molecular function
DNA binding;satellite DNA binding;endodeoxyribonuclease activity;protein binding;pyrimidine-specific mismatch base pair DNA N-glycosylase activity;DNA N-glycosylase activity